Project Grant HT94252310445
Award Date 7/1/23
Completion Date 6/30/26
Dollars Obligated $846K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...
- The Sloan-Kettering Institute for Cancer Research was awarded a $707,346 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2024, supports Sloan-Kettering's cancer research initiatives, including investigations into the tumor microenvironment, mechanisms of metastasis, epigenetic alterations in cancer, resistance to cancer therapies, aging-related biology, and hematologic malignancies....
- The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
- The Sloan-Kettering Institute for Cancer Research received a $1.63 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 15, 2025, for the McCain/Bayh Glioblastoma Consortium. The award, which extends through September 14, 2029, supports research and development activities focused on glioblastoma treatment and innovation. As a premier cancer research institution with extensive federal funding...
- This $176,000 Project Grant awarded by the Department of Defense (DOD) through the Military Medical Research and Development program (CFDA 12.420) supports research by the Sloan-Kettering Institute for Cancer Research to define the biology of and identify therapeutic vulnerabilities in DCK12-inactivated prostate cancer. The award period is from April 1, 2024 to March 31, 2025. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute has previously...
- The Sloan-Kettering Institute for Cancer Research was awarded a $906,740 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an application for following images of nevi (moles) to detect melanoma. The project will be conducted over a 3-year period from August 1, 2023 to July 31, 2026. Through this federal grant, the Sloan-Kettering Institute, a non-profit research organization, will focus on innovative and impactful...
- The Sloan-Kettering Institute for Cancer Research was awarded a $923,999 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the effects of tobacco smoking on African American patients with lung cancer. The award will support a multi-year research initiative from July 1, 2024 to June 30, 2027. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute for...
- The Sloan-Kettering Institute for Cancer Research was awarded a $1,295,691 Project Grant on November 1, 2024 under the Military Medical Research and Development (CFDA 12.420) federal grant program, administered by the Defense Health Agency. The funding will support research aimed at "Targeting Hypermethylation to Overcome Cisplatin Resistance in Patients with Relapsed/Refractory Germ Cell Tumors" over a performance period ending on October 31, 2027. As a leading comprehensive cancer...
- This $664,456 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research. The award will fund a 3-year research project focused on investigating biomarkers of immune response in mismatch repair-deficient (MMR-D) endometrial cancer treated with immune checkpoint blockade and radiation. The research aims to advance the understanding of cancer immunology and develop new...
- Federal Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2026. This award supports research investigating the interactions of mitochondrially encoded Complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to advance...